GANX (Gain Therapeutics) Beginning Cash Position: $20.87 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GANX Gain Therapeutics Inc GANX
31 GF Score
Price $1.63
! 2 Warning Signs
View Full Analysis

What is Gain Therapeutics Beginning Cash Position?

Gain Therapeutics GANX -4.40% 31 Beginning Cash Position is $20.87 Mil as of Mar. 2026. GuruFocus rates GANX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Gain Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $20.87 Mil.

Gain Therapeutics's quarterly Beginning Cash Position increased from Sep. 2025 ($6.73 Mil) to Dec. 2025 ($8.84 Mil) and increased from Dec. 2025 ($8.84 Mil) to Mar. 2026 ($20.87 Mil).

Gain Therapeutics's annual Beginning Cash Position increased from Dec. 2023 ($7.34 Mil) to Dec. 2024 ($11.83 Mil) but then declined from Dec. 2024 ($11.83 Mil) to Dec. 2025 ($10.42 Mil).

Gain Therapeutics Beginning Cash Position Related Terms

Gain Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Gain Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gain Therapeutics Beginning Cash Position Chart

Gain Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 7.50 36.91 7.34 11.83 10.42

Gain Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.42 9.10 6.73 8.84 20.87
GANX
31GF Score
Gain Therapeutics Inc GANX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gain Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $20.87 Mil mean?
Gain Therapeutics (GANX) has a Beginning Cash Position of $20.87 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Gain Therapeutics and its competitors.
Is Gain Therapeutics' Beginning Cash Position too high?
Gain Therapeutics' current Beginning Cash Position is $20.87 Mil. Overall, Gain Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Gain Therapeutics' Beginning Cash Position compare to HYFT and ELTX?
Gain Therapeutics' Beginning Cash Position of $20.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Gain Therapeutics and its competitors. Gain Therapeutics's current Beginning Cash Position is $20.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gain Therapeutics stock overvalued right now?
Gain Therapeutics (GANX) has a current Beginning Cash Position of $20.87 Mil. The current Beginning Cash Position is $20.87 Mil. Gain Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Gain Therapeutics (GANX), the current Beginning Cash Position is $20.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gain Therapeutics Business Description

Address 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
31GF Score

Get the complete analysis for GANX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.63
Price